Dicot Pharma
0.226
SEK
-2.38 %
DICOT
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
1 following
-2.38%
-11.55%
+36.97%
+19.32%
+23.16%
-3.37%
+81.82%
-36.29%
-77.44%
-91.16%
www.dicotpharma.com/investor-relations
Dicot Pharma is developing the drug candidate LIB-01, which is expected to be a potency drug to treat erectile dysfunction and premature ejaculation. Duration of action and fewer side effects are main desired properties. Dicot's main strategy is to develop LIB-01 in-house up to and including clinical phase 2a study, and then in partnership with major pharmaceutical companies to finance and further develop LIB-01 into a registered drug for the world market.
Revenue
230K
EBIT %
-19,569.57 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
DICOT
Daily low / high price
0.216 / 0.238
SEK
Market cap
402M SEK
Turnover
810.55K SEK
Volume
3.6M
Financial calendar
Annual report
2025-02-13
Interim report
2025-04-29
General meeting
2025-05-06
Interim report
2025-08-12
Interim report
2025-10-23
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Avanza Pension | 10.5 % | 10.5 % |
| Bertil Lindkvist (Ålandsbanken) | 7.6 % | 7.6 % |
| Nordnet Pensionsförsäkring | 3.6 % | 3.6 % |
| Tor Finans AB | 3.2 % | 3.2 % |
| Torsten Söderberg med familj | 1.9 % | 1.9 % |
| Stefan Henriksson | 1.3 % | 1.3 % |
| Christian och Gerd Lentz | 1.2 % | 1.2 % |
| Klas Göran Strömberg | 1.0 % | 1.0 % |
| Wilhelm Risberg | 0.9 % | 0.9 % |
| Michael Zell | 0.9 % | 0.9 % |
ShowingAll content types
Dicot Pharma AB: First participants dosed in Dicot Pharma's Phase 2a clinical study
Dicot Pharma AB: International business development expert joins Dicot Pharma
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools